[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350973-105":3,"doc-detail-350973-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","characterization-of-esr1-alterations-in-patients-with-breast-and-gynecologic-cancers-research-findings","Characterization of ESR1 alterations in patients with breast and gynecologic cancers - Research findings","","ESR1 alterations are a widespread mechanism behind resistance to endocrine therapy in hormone-driven tumors, with clinical meaning still developing as targeted treatments and trials expand. A retrospective cohort of 2,574 breast cancer and 1,110 gynecologic cancer samples was profiled using whole exome and whole transcriptome methods to map ESR1 alterations and co-alterations by site and major breast subtypes. ESR1 alterations were more frequent in metastatic compared with local/regional samples within HR+/HER2- disease, and therapeutically actionable co-alterations emerged mainly in ESR1-altered HR+/HER2- breast cancer.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/characterization-of-esr1-alterations-in-patients-with-breast-and-gynecologic-cancers-research-findings/350973/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/characterization-of-esr1-alterations-in-patients-with-breast-and-gynecologic-cancers-research-findings/350973.png","ImageObject",300,407,{"name":42,"@type":43},"Hazel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is ESR1 and why are ESR1 alterations important?","Question",{"text":63,"@type":64},"ESR1 encodes estrogen receptor α, which controls gene expression related to tumor differentiation and survival. The document links ESR1 alterations to endocrine therapy resistance in hormone receptor–positive cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was ESR1 alterations distribution assessed in the study?",{"text":68,"@type":64},"The study used retrospective profiling of 2,574 breast cancer and 1,110 gynecologic cancer samples with whole exome and whole transcriptome methods. Results were compared between local/regional versus metastatic sites and across major breast cancer subtypes.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find about metastatic versus local/regional samples?",{"text":72,"@type":64},"Within HR+/HER2- breast cancer, ESR1 alterations and ESR1 missense mutations were more frequent in metastatic samples than in local/regional samples, with statistical significance reported in the results.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350973,1790538305,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984",8,"Basu etal. Breast Cancer Research (2026) 28:40 Breast Cancer Research  \n[https://doi.org/10.1186/s13058-025-02217-0](https://doi.org/10.1186/s13058-025-02217-0)  \nRESEARCH Open Access  \nCharacterization of ESR1 alterations in patients with breast and gynecologic cancers  \nGargi D. Basu 1, Paige E. Innis 1, Angela K. Deem 1, Arthur Starodynov1, Sameer S. Udhane 1, Szabolcs Szelinger1, Min Wang1, Janine R. LoBello 1, Frederick L. Baehner 1, Jean-Paul De La O1 and Joyce O’Shaughnessy2*  \nAbstract  \nBackground ESR1 alterations present a common mechanism of resistance to endocrine therapy (ET) in hormonally driven tumors. The clinical significance of these alterations continues to evolve with newly approved targeted therapies and a range of ongoing investigational trials.  \nMethods A retrospective study of 2574 breast cancer (BC) and 1110 gynecologic cancer samples that underwent whole exome and whole transcriptome profiling was conducted to assess the distribution of ESR1 and associated co-alterations in local (primary breast or regional lymph node) versus metastatic BC samples and in the major BC subtypes. Prior treatment history was unknown.  \nResults ESR1 alterations were present in 6 . 2%(n = 159/2574) of BC samples and 3 .4%(n = 38/1110) of gynecologic cancer samples. In HR + /HER2-BC, ESR1 alterations overall and ESR1 missense mutations were more frequent in samples from metastatic compared to local/regional sites (overall: n = 86/321 (26 . 8%) and n = 53/1427 (3 . 7%), respectively (P \u003C 0. 001); missense: n = 72/321 (22 .4%) and n = 20/1427 (1 .4%), respectively (P \u003C 0. 001)) . Whole transcriptome sequencing detected ESR1 fusion genes in 2. 1%(n = 55/2574) of BC samples and in 1. 9%(n = 21/1110) of gynecologic cancer samples, and CCDC170 was the most common fusion partner in both cancer types. In HR +/ HER2-BC, ESR1 fusions were more common in metastatic samples compared to local/regional (n = 17/321 (5 . 3%) and n = 29/1427 (2 . 0%), respectively; P \u003C 0. 001) . Evaluation of 21 therapeutically actionable biomarkers identified co-alterations enriched in ESR1-altered HR + /HER2-BC, including FGF3/4/19 and CCND1 amplifications. No significant co-alterations were found in gynecologic cancer samples.  \nConclusions ESR1 alterations were most frequent in HR + /HER2-BC samples and missense mutations were more frequent in metastatic samples, consistent with their role in ET resistance and disease progression. ESR1 alterations co-occurred with therapeutically relevant alterations in other genes that may help inform clinical decision-making. Gynecologic tumors harbored ESR1 alterations that have prognostic and potentially therapeutic relevance. Keywords Estrogen receptor, Resistance, Breast cancer, Gynecologic cancers, Comprehensive genomic profiling  \n*Correspondence:  \nJoyce O’Shaughnessy  \n[joyce.oshaughnessy@usoncology.com](joyce.oshaughnessy@usoncology.com)  \n1Exact Sciences Corporation, 5505 Endeavor Ln, Madison, WI 53719, USA 2Baylor University Medical Center, Texas Oncology, Sarah Cannon Research Institute, 3410 Worth Street, Suite 400, Dallas, TX 75246, USA  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://c","cbCaibQQdeyRWoNR","https://ap.wps.com/l/cbCaibQQdeyRWoNR","pdf",2748131,18,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Key biological context: estrogen receptor and ESR1\n## ESR and endocrine therapy resistance in hormone receptor-positive tumors","[{\"question\":\"What is ESR1 and why are ESR1 alterations important?\",\"answer\":\"ESR1 encodes estrogen receptor α, which controls gene expression related to tumor differentiation and survival. The document links ESR1 alterations to endocrine therapy resistance in hormone receptor–positive cancers.\"},{\"question\":\"How was ESR1 alterations distribution assessed in the study?\",\"answer\":\"The study used retrospective profiling of 2,574 breast cancer and 1,110 gynecologic cancer samples with whole exome and whole transcriptome methods. Results were compared between local/regional versus metastatic sites and across major breast cancer subtypes.\"},{\"question\":\"What did the study find about metastatic versus local/regional samples?\",\"answer\":\"Within HR+/HER2- breast cancer, ESR1 alterations and ESR1 missense mutations were more frequent in metastatic samples than in local/regional samples, with statistical significance reported in the results.\"}]","Characterization of ESR1 alterations in patients with breast and gynecologic cancers - Research findings | PDF",1790092150,45,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/17da6654cd0867b1def9a38f3b0962e2.webp",983,1310,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2fe7321ba3df583a8aac7215b7716fc.webp",982,1309,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d342a9f05c9b2c19b33fcd4539542246.webp",981,1308,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e1b57666a99113f0a9a35df34f1f2ca.webp",980,1306,{"code":4,"msg":82,"data":117},[118,122,126,130,135,140,145,148,153,156,160],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":25,"category_name":137,"show_sort_weight":138,"slug":139},6,"Technology",50,"technology",{"id":141,"doc_module":4,"doc_module_name":25,"category_name":142,"show_sort_weight":143,"slug":144},7,"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":146,"slug":147},30,"research-report",{"id":149,"doc_module":4,"doc_module_name":25,"category_name":150,"show_sort_weight":151,"slug":152},9,"Religion & Spirituality",20,"religion-spirituality",{"id":151,"doc_module":4,"doc_module_name":25,"category_name":154,"show_sort_weight":151,"slug":155},"World Cup","world-cup",{"id":157,"doc_module":4,"doc_module_name":25,"category_name":158,"show_sort_weight":157,"slug":159},10,"Lifestyle","lifestyle",{"id":161,"doc_module":4,"doc_module_name":25,"category_name":162,"show_sort_weight":131,"slug":163},19,"General","general"]